Bioatla, Inc. (BCAB)
NASDAQ:BCAB
BCAB Stock Chart & Stats
$0.19
-$0.03(-5.55%)
At close: 4:00 PM EST
$0.19
-$0.03(-5.55%)
Day’s Range― - ―
52-Week Range$3.92 - $71.50
Previous CloseN/A
Volume775.41K
Average Volume (3M)40.55K
Market Cap
$7.39M
Enterprise Value$4.33M
Total Cash (Recent Filing)$7.12M
Total Debt (Recent Filing)$6.20M
Price to Earnings (P/E)―
Beta2.24
Next Earnings
May 13, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-8.00
Shares Outstanding1,656,926
10 Day Avg. Volume63,949
30 Day Avg. Volume40,550
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)-0.92
Price to Sales (P/S)16.70
P/FCF Ratio-0.69
Enterprise Value/Market Cap0.59
Enterprise Value/Revenue2.16
Enterprise Value/Gross Profit2.16
Enterprise Value/Ebitda-0.07
Forecast
1Y Price Target
$4.00Price Target Upside2005.26% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-46
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
FDA Alignment On Phase 3 DesignRegulatory alignment on a Phase 3 registrational design with dual primary endpoints (ORR and OS) materially reduces development risk and clarifies the pathway to accelerated then full approval. This durable de‑risking improves partnerability and the probability of a commercial launch if trials succeed.
Compelling Phase 2 OSV DataRobust Phase 2 efficacy (45% ORR; 11.6m median OS) versus historical controls indicates clinical differentiation in a hard-to-treat indication. That durable efficacy signal supports a credible commercial profile, strengthens Phase 3 design confidence, and enhances licensing or partnering leverage.
External Milestone / Non-dilutive CapitalA paid milestone from a partner validates the CAB T cell engager platform and delivers non-dilutive funding. Continued partner-funded milestones and licensing pathways provide a sustainable financing alternative to equity raises and signal external scientific and commercial interest.
Bears Say
Negative Shareholders' EquityMaterial balance sheet erosion and negative equity reflect accumulated losses and asset depletion, which permanently weaken financial flexibility. Negative equity raises creditor and covenant risks, complicates secured financing and M&A negotiations and increases likelihood of dilutive capital raises.
Persistent Cash BurnConsistent negative operating and free cash flow demonstrate the business is not self-sustaining; even with an improved burn trend, the company must secure external capital to fund pivotal trials. That ongoing funding dependency increases dilution risk and makes long-term programs contingent on financings or partnerships.
Listing Risk And Major RestructuringA deep workforce reduction, CFO turnover and active Nasdaq delisting review materially raise execution risk. Cuts may delay programs and reduce institutional confidence; listing uncertainty and governance maneuvers complicate capital access and strategic transactions over the next several months.
BioAtla News
BCAB FAQ
What was Bioatla, Inc.’s price range in the past 12 months?
Bioatla, Inc. lowest stock price was $3.92 and its highest was $71.50 in the past 12 months.
What is Bioatla, Inc.’s market cap?
Bioatla, Inc.’s market cap is $7.39M.
When is Bioatla, Inc.’s upcoming earnings report date?
Bioatla, Inc.’s upcoming earnings report date is May 13, 2026 which is in 30 days.
How were Bioatla, Inc.’s earnings last quarter?
Bioatla, Inc. released its earnings results on Mar 31, 2026. The company reported -$8 earnings per share for the quarter, beating the consensus estimate of -$12 by $4.
Is Bioatla, Inc. overvalued?
According to Wall Street analysts Bioatla, Inc.’s price is currently Undervalued.
Does Bioatla, Inc. pay dividends?
Bioatla, Inc. does not currently pay dividends.
What is Bioatla, Inc.’s EPS estimate?
Bioatla, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Bioatla, Inc. have?
Bioatla, Inc. has 1,656,926 shares outstanding.
What happened to Bioatla, Inc.’s price movement after its last earnings report?
Bioatla, Inc. reported an EPS of -$8 in its last earnings report, beating expectations of -$12. Following the earnings report the stock price went down -16.398%.
Which hedge fund is a major shareholder of Bioatla, Inc.?
Currently, no hedge funds are holding shares in BCAB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Bioatla, Inc.
BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer. It also develops BA3021, a CAB ADC for multiple solid tumor types, including NSCLC, melanoma, and ovarian cancer; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. BioAtla, Inc. was founded in 2007 and is based in San Diego, California.
BCAB Stock 12 Month Forecast
Average Price Target
$4.00
▲(2005.26% Upside)
Technical Analysis
Actinium Pharmaceuticals
―
―
Lantern Pharma
―
Century Therapeutics
―
MAIA Biotechnology, Inc.
―
Ownership Overview
8.61% Insiders
3.05% Mutual Funds
7.55% Other Institutional Investors
77.46% Public Companies and
Individual Investors